Yamamoto Akinaru, Nakai Yasutomo, Oka Toshiki, Kanaki Tomohiro, Yamamoto Yoshiyuki, Nagahara Akira, Nakayama Masashi, Kakimoto Ken-Ichi, Nishimura Kazuo
Department of Urology Osaka International Cancer Institute Osaka City Osaka Japan.
IJU Case Rep. 2020 Aug 30;3(6):270-273. doi: 10.1002/iju5.12214. eCollection 2020 Nov.
Adrenocortical carcinoma is a rare malignant tumor with an unfavorable prognosis in the advanced stage for which second-/third-line chemotherapy is not well established.
A 34-year-old woman was referred to our institution for left adrenal tumor with multiple liver metastases and tumor thrombus extending to the inferior vena cava. According to her clinical diagnosis of adrenocortical carcinoma (T4N0M1, European Network for the Study of Adrenal Tumors stage IV), we resected the left adrenal tumor and tumor thrombus. Pathological examination confirmed the adrenocortical carcinoma diagnosis. After four courses of etoposide, doxorubicin, cisplatin, and mitotane therapy, the liver metastases progressed, and we started gemcitabine, capecitabine, and mitotane therapy as second-line chemotherapy. After 7 months, significant shrinkage of the liver metastases was observed, and they remained stable over 16 months.
We reported a case of advanced adrenocortical carcinoma with significant shrinkage of liver metastases following gemcitabine, capecitabine, and mitotane therapy, with the effect maintained over 16 months.
肾上腺皮质癌是一种罕见的恶性肿瘤,晚期预后不佳,二线/三线化疗方案尚未确立。
一名34岁女性因左肾上腺肿瘤伴多发肝转移及肿瘤血栓延伸至下腔静脉被转诊至我院。根据其肾上腺皮质癌的临床诊断(欧洲肾上腺肿瘤研究网络IV期,T4N0M1),我们切除了左肾上腺肿瘤及肿瘤血栓。病理检查确诊为肾上腺皮质癌。在接受依托泊苷、阿霉素、顺铂和米托坦四个疗程的治疗后,肝转移进展,我们开始使用吉西他滨、卡培他滨和米托坦作为二线化疗。7个月后,观察到肝转移灶明显缩小,并在16个月内保持稳定。
我们报告了一例晚期肾上腺皮质癌患者,在接受吉西他滨、卡培他滨和米托坦治疗后,肝转移灶明显缩小,且疗效维持了16个月。